Search
Imiquimod
go.drugbank.com/drugs/DB00724ApprovedInvestigationalImiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. … Miquimod is also used to treat a skin condition of the face and scalp called actinic keratoses and certain types of skin cancer called superficial basal cell carcinoma.
International brands: Li DiVilobelimab
go.drugbank.com/drugs/DB16416ApprovedInvestigational[L45839] In April 2023, the FDA issued an emergency use authorization (EUA) for vilobelimab for the treatment of COVID-19 in hospitalized adults requiring mechanical ventilation or artificial life support … Vilobelimab is a chimeric monoclonal immunoglobulin G4 (IgG4) antibody that binds to the soluble form of human C5a with high affinity.
Siponimod
go.drugbank.com/drugs/DB12371ApprovedInvestigational[L12171] This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA … [L5801] MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexEltrombopag
go.drugbank.com/drugs/DB06210ApprovedInvestigationalITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. … Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked
Talimogene laherparepvec
go.drugbank.com/drugs/DB13896ApprovedInvestigationalTalimogene laherparepvec is an oncolytic treatment used in local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma. … It is a genetically administered herpes simplex virus 1 (HSV-1) that expresses human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with antitumor and immune-stimulating activities.
Aluminum sesquichlorohydrate
go.drugbank.com/drugs/DB11108ApprovedAluminum sesquichlorohydrate is an aluminum salt used as an antiperspirant agent, cosmetic astringent and deodorant agent. It works by physically blocking eccrine sweat gland ducts [A31171].
Mixtures: Lactovit DEODORANT ROLL-ON MEN INVISIBLE, Lactovit Mens Roll On Antiperspirant DeodorantProducts: AINNARA Roll-On, CARDIGAN Roll-OnAminopterin
go.drugbank.com/drugs/DB08878ApprovedWithdrawnIn the 1950's its production was discontinued in favor of methotrexate, which is less potent but less toxic. Off label, aminopterin has also been used in the treatment of psoriasis. … Aminopterin is an amino derivative of folic acid, which was once used as an antineoplastic agent in the treatment of pediatric leukemia.
Synonyms: N-(4-(((2,4-diamino-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acidEchothiophate
go.drugbank.com/drugs/DB01057ApprovedInvestigationalA potent, long-acting irreversible cholinesterase inhibitor used as an ocular hypertensive in the treatment of glaucoma. Occasionally used for accomodative esotropia.
Synonyms: 2-(Diethoxyphosphorylsulfanyl)ethyl-N,N,N-trimethylazanium iodideBenziodarone
go.drugbank.com/drugs/DB13277ApprovedWithdrawnBenziodarone is a uricostatic and a uricosuric agent which is sold also under the name Amplivex-Labaz. It is used in the treatment of gout [A175630]. … It was withdrawn from France markets and British markets due to its effects causing Jaundice in patients [T487, A175636].
Categories: Vasodilators Used in Cardiac DiseasesLunsotogene parvec
go.drugbank.com/drugs/DB18278ApprovedInvestigationalIt is the first gene therapy to be approved under the Commissioner's National Priority Voucher (CNPV) pilot and represents one of the fastest BLA approvals in modern history, with a time between filing … Lunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss.